BDX - FDA Probe On China-Made Syringes: Becton Dickinson Boosts US Syringe Output Following Concerns | Benzinga
Thursday, Becton Dickinson And Co (NYSE:BDX) said it increased production of medical syringes in the U.S. after the FDA recommended not using some China-made syringes as part of its ongoing quality probe.
Eric Borin, president of BD Medication Delivery Solutions, said, “BD has the capacity to support additional syringe demand and is further increasing U.S. production to help ensure continuity of patient care. Since the initial FDA safety communication in November, BD has increased domestic manufacturing of syringes in our Nebraska and Connecticut facilities to respond to customer needs.”
In November 2023, the ...